What is AstraZeneca's expected EPS for Q2 2026?

Analysts expect AstraZeneca (AZN) to report consensus EPS of approximately $1.27 for Q2 2026. Estimates range from $1.25 to $1.29.

What revenue do analysts expect for AstraZeneca in Q2 2026?

The consensus revenue forecast for AstraZeneca (AZN) in Q2 2026 is approximately $15.4B. Forecasts range from $15.2B to $15.7B.

How many analysts cover AstraZeneca?

2 analysts contribute to the AstraZeneca (AZN) Q2 2026 consensus estimate.

Has AstraZeneca beaten earnings estimates recently?

AstraZeneca beat analyst EPS estimates in 1 of the last 2 quarters. AstraZeneca beat revenue estimates in 2 of 2. In the most recent quarter (Q1 2026), AstraZeneca EPS beat by 2.4% and revenue beat by 2.4%.

When does AstraZeneca report Q2 2026 earnings?

AstraZeneca (AZN) is expected to report Q2 2026 earnings on July 27, 2026 after market close.

AZN Q2 2026 earnings estimate

Consensus EPS · Q2 2026

$1.27

Consensus revenue · Q2 2026

$15.4B

Analysts

Expected report

Jul 27, 2026

After close

Upcoming earnings

Locks in 4 days 7 hours · AMC: Locks at 4:00 PM ET on report day

Revenue$15.4B$15.2B – $15.7B

EPS$1.27$1.25 – $1.29

What to watch

Analyst ratings: Mixed

Make your prediction

Analyst consensus

Based on estimates from 2 analysts.

Metric	Low	Consensus	High
Revenue	$15.2B	$15.4B	$15.7B
EPS	$1.25	$1.27	$1.29
EBITDA	$7.8B	$8B	$8.1B
EBIT	$6.7B	$6.8B	$6.9B
Net income	$1.9B	$1.9B	$2B

Revenue$15.4B
EPS$1.27
EBITDA$8B
EBIT$6.8B
Net income$1.9B

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q1 2026	$15.3B	$14.9B	+2.4%	$2.58	$2.52	+2.4%
Q4 2025	$15.5B	$15.4B	+0.4%	$1.06	$2.09	-49.3%

Q1 2026+2.4%+2.4%
Q4 2025+0.4%-49.3%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Grade F — Strong downward revisions

Metric	Now	30d ago	60d ago	90d ago	30d Δ
Revenue	$15.5B	$15.5B	—	—	-0.0%
EPS	$2.48	$2.50	—	—	-0.5%

0 revised up (30d)2 revised down (30d)

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for AstraZeneca (AZN) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 0 analysts.

Low: $158.00
Consensus: $186.67
Median: $185.00
High: $216.00
Current: $169.73
Upside: +10.0%

Upside calculated vs most recent trading price of $169.73.

Analyst ratings

Consensus: Buy — based on 41 analyst ratings.

Strong Buy 1Buy 19Hold 15Sell 6

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Feb 13, 2025	UBS	upgrade	Neutral	Buy
Nov 20, 2024	UBS	upgrade	Sell	Neutral
Sep 11, 2024	Erste Group	upgrade	Hold	Buy
Aug 12, 2024	TD Cowen	maintain	Buy	Buy
May 30, 2024	Argus Research	maintain	Buy	Buy
Apr 26, 2024	BMO Capital	maintain	Outperform	Outperform
Apr 16, 2024	Deutsche Bank	upgrade	Sell	Hold
Feb 12, 2024	BMO Capital	maintain	Outperform	Outperform
Feb 8, 2024	Deutsche Bank	downgrade	Buy	Hold
Jan 3, 2024	Jefferies	downgrade	Buy	Hold

Feb 13, 2025UBSBuy
Nov 20, 2024UBSNeutral
Sep 11, 2024Erste GroupBuy
Aug 12, 2024TD CowenBuy
May 30, 2024Argus ResearchBuy
Apr 26, 2024BMO CapitalOutperform
Apr 16, 2024Deutsche BankHold
Feb 12, 2024BMO CapitalOutperform
Feb 8, 2024Deutsche BankHold
Jan 3, 2024JefferiesHold

Frequently asked questions

AstraZeneca (AZN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

AZN Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation